The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued ...